Supercharged immune cells battle tough blood cancers in new trial
NCT ID NCT04684563
Summary
This early-stage trial is testing a new version of CAR-T cell therapy called huCART19-IL18 for adults with certain blood cancers that have returned or not responded to standard treatments. The study aims to find a safe dose and see if the therapy can be reliably manufactured. It focuses on patients with CD19-positive cancers like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.